LIH CHYUN CHANGHu, Hsiang-WeiHsiang-WeiHuMIN-SHU HSIEHSHANG-GIN WUJIN-YUAN SHIH2025-05-022025-05-022025-03-21https://scholars.lib.ntu.edu.tw/handle/123456789/728781No significant difference in progression-free survival and overall survival with osimertinib was observed between E746del (deletions starting at codon E746) and L747del (deletions starting at codon L747) mutations. • EGFR exon 19 non-LRE deletions, which do not include the entire LRE fragment, may be linked to a poorer prognosis in patients receiving osimertinib treatment. • Rare EGFR exon 19 mutations demonstrated diverse responses to osimertinib.enDeletion in exon 19Epidermal growth factor receptorRare EGFR mutationSurvival outcomesTargeted therapy[SDGs]SDG3journal article10.1016/j.cllc.2025.03.00840221329